---
document_datetime: 2025-07-11 09:22:29
document_pages: 2
document_pathfilename: www.ema.europa.eu/en/documents/procedural-steps-after/capecitabine-teva-epar-procedural-steps-taken-scientific-information-after-authorisation_en.pdf
document_name: capecitabine-teva-epar-procedural-steps-taken-scientific-information-after-authorisation_en.pdf
version: success
processing_time: 1.6883289
conversion_datetime: 2025-12-30 13:03:38.856113
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.66.0
  docling-core: 2.57.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
## Capecitabine Teva

Procedural steps taken and scientific information after the authorisation*

*Due to the Agency`s update of its procedure management systems, an additional document, reflecting the historical lifecycle may be available in the 'Assessment history' section. For the complete product lifecycle procedures, you may need to also refer to EPAR - Procedural steps taken and scientific information after authorisation (archive) .

| Application number   | Scope                                     | Opinion/ Notification 1 issued on   | Commission Decision Issued 2 / amended on   | Product Information affected 3   | Summary                                      |
|----------------------|-------------------------------------------|-------------------------------------|---------------------------------------------|----------------------------------|----------------------------------------------|
| Variation type IB /  | C.I.2 Change(s) in the Summary of Product | 10/07/2025                          |                                             | SmPC,                            | To update Section 4.4 of the SmPC to amend a |

<!-- image -->

<!-- image -->

<div style=\"page-break-after: always\"></div>

| EMA/VR/0000282000   | Labelling and PL   | warning on phenotyping for DPD deficiency. The change follows assessment of the same change for the reference product, Xeloda.   |
|---------------------|--------------------|----------------------------------------------------------------------------------------------------------------------------------|